MBRX
Income statement / Annual
Last year (2025), Moleculin Biotech Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Moleculin Biotech Inc's net income was -$33.56 M.
See Moleculin Biotech Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$90.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$185.00 K
|
$68.00 K
|
$18.00 K
|
$6.16 K
|
| Gross Profit |
-$90.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$185.00 K
|
-$68.00 K
|
-$18.00 K
|
-$6.16 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$15.89 M
|
$17.73 M
|
$19.49 M
|
$18.97 M
|
$14.42 M
|
$12.76 M
|
$11.01 M
|
$9.73 M
|
$4.55 M
|
$1.50 M
|
| General & Administrative Expenses |
$9.12 M
|
$8.79 M
|
$10.02 M
|
$11.54 M
|
$8.39 M
|
$6.79 M
|
$0.00
|
$5.30 M
|
$4.09 M
|
$2.38 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.12 M
|
$8.79 M
|
$10.02 M
|
$11.54 M
|
$8.39 M
|
$6.79 M
|
$6.33 M
|
$5.30 M
|
$4.09 M
|
$2.38 M
|
| Other Expenses |
$90.00 K
|
$126.00 K
|
$127.00 K
|
$130.00 K
|
$164.00 K
|
$200.00 K
|
$0.00
|
-$40.00 K
|
$18.00 K
|
$6.16 K
|
| Operating Expenses |
$25.10 M
|
$26.64 M
|
$29.63 M
|
$30.64 M
|
$22.97 M
|
$19.74 M
|
$17.34 M
|
$15.03 M
|
$8.65 M
|
$3.88 M
|
| Cost And Expenses |
$25.10 M
|
$26.64 M
|
$29.63 M
|
$30.64 M
|
$22.97 M
|
$19.74 M
|
$17.52 M
|
$15.03 M
|
$8.65 M
|
$3.88 M
|
| Interest Income |
$105.00 K
|
$550.00 K
|
$1.37 M
|
$240.00 K
|
$306.00 K
|
$13.00 K
|
$13.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$43.21 K
|
| Depreciation & Amortization |
$90.00 K
|
$126.00 K
|
$127.00 K
|
$130.00 K
|
$164.00 K
|
$200.00 K
|
$185.00 K
|
$68.00 K
|
$18.00 K
|
$6.16 K
|
| EBITDA |
-$33.47 M |
-$21.64 M |
-$29.64 M |
-$28.90 M |
-$15.73 M |
-$19.54 M |
-$13.25 M |
-$14.96 M |
-$8.64 M |
-$3.88 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$8.46 M
|
$4.88 M
|
-$138.00 K
|
$1.62 M
|
$7.07 M
|
$2.39 M
|
$4.09 M
|
$3.15 M
|
-$1.15 M
|
-$43.36 K
|
| Income Before Tax |
-$33.56 M
|
-$21.76 M
|
-$29.77 M
|
-$29.03 M
|
-$15.89 M
|
-$17.36 M
|
-$13.43 M
|
-$11.88 M
|
-$9.81 M
|
-$3.93 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$229.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$33.56 M
|
-$21.76 M
|
-$29.77 M
|
-$29.03 M
|
-$15.89 M
|
-$17.36 M
|
-$13.21 M
|
-$11.88 M
|
-$9.81 M
|
-$3.93 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-28.42 |
-189.14 |
-376.71 |
-380.51 |
-221.77 |
-661 |
-729.63 |
-1031.54 |
-1188.07 |
-900 |
| EPS Diluted |
-28.42 |
-189.14 |
-376.71 |
-380.51 |
-221.77 |
-661 |
-729.63 |
-1031.54 |
-1188.07 |
-900 |
| Weighted Average Shares Out |
$1.18 M
|
$137.72 K
|
$79.02 K
|
$76.28 K
|
$71.67 K
|
$26.26 K
|
$18.10 K
|
$11.51 K
|
$8.25 K
|
$4.37 K
|
| Weighted Average Shares Out Diluted |
$1.18 M
|
$137.72 K
|
$79.02 K
|
$76.28 K
|
$71.67 K
|
$26.26 K
|
$18.10 K
|
$11.51 K
|
$8.25 K
|
$4.37 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
